64x Bio
64x Bio is a series A-stage biotech company originating from Harvard Medical School and the Wyss Institute. Using novel high throughput genome engineering and screening technologies in a design loop with computational tools, 64x Bio is developing highly optimized cell lines, as well as other tools and technologies for the manufacturing of viral vectors. These fundamental advances enable pharmaceutical and biotechnology companies to bring more lifesaving cell and gene therapies to patients by reducing the cost and complexity of manufacturing, a critical bottleneck in this growing market. The company’s co-founders include Lexi Rovner, George Church, Pam Silver, Jeff Way, David Thompson & Farhad Paylakhi. 64x Bio is backed by prominent investors such as First Round Capital and Y Combinator. The company is based in Brisbane and Boston. For more information, visit www.64xbio.com and follow us on Twitter @64xbio.
